- Home
- HURN vs AKRO Comparison
HURN vs AKRO Comparison
Compare HURN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- AKRO
- Stock Information
- Founded
- HURN 2002
- AKRO 2017
- Country
- HURN United States
- AKRO United States
- Employees
- HURN N/A
- AKRO N/A
- Industry
- HURN Professional Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- AKRO Health Care
- Exchange
- HURN Nasdaq
- AKRO Nasdaq
- Market Cap
- HURN 2.6B
- AKRO 3.9B
- IPO Year
- HURN 2004
- AKRO 2019
- Fundamental
- Price
- HURN $138.39
- AKRO $51.88
- Analyst Decision
- HURN Strong Buy
- AKRO Strong Buy
- Analyst Count
- HURN 4
- AKRO 6
- Target Price
- HURN $170.75
- AKRO $82.50
- AVG Volume (30 Days)
- HURN 193.0K
- AKRO 1.7M
- Earning Date
- HURN 07-29-2025
- AKRO 08-08-2025
- Dividend Yield
- HURN N/A
- AKRO N/A
- EPS Growth
- HURN 92.74
- AKRO N/A
- EPS
- HURN 6.67
- AKRO N/A
- Revenue
- HURN $1,525,814,000.00
- AKRO N/A
- Revenue This Year
- HURN $11.50
- AKRO N/A
- Revenue Next Year
- HURN $7.48
- AKRO N/A
- P/E Ratio
- HURN $20.79
- AKRO N/A
- Revenue Growth
- HURN 8.98
- AKRO N/A
- 52 Week Low
- HURN $96.45
- AKRO $21.02
- 52 Week High
- HURN $155.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- HURN 49.79
- AKRO 49.53
- Support Level
- HURN $130.72
- AKRO $53.05
- Resistance Level
- HURN $140.77
- AKRO $57.35
- Average True Range (ATR)
- HURN 3.29
- AKRO 2.34
- MACD
- HURN 0.61
- AKRO -0.75
- Stochastic Oscillator
- HURN 76.32
- AKRO 12.83
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.